| Literature DB >> 33903730 |
Maria Davern1,2, Noel E Donlon1,2, Margaret R Dunne1,2, Robert Power1,2, Conall Hayes1,2, Ross King1,2, John V Reynolds3,4.
Abstract
Oesophageal cancer (OC) is an inflammation-associated malignancy linked to gastro-oesophageal reflux disease, obesity and tobacco use. Knowledge of the microenvironment of oesophageal tumours is relevant to our understanding of the development of OC and its biology, and has major implications for understanding the response to standard therapies and immunotherapies, as well as for uncovering novel targets. In this context, we discuss what is known about the TME in OC from tumour initiation to development and progression, and how this is relevant to therapy sensitivity and resistance in the two major types of OC. We provide an immunological characterisation of the OC TME and discuss its prognostic implications with specific comparison with the Immunoscore and immune-hot, -cold, altered-immunosuppressed and -altered-excluded models. Targeted therapeutics for the TME under pre-clinical and clinical investigation in OCs are also summarised. A deeper understanding of the TME will enable the development of combination approaches to concurrently target the tumour cells and TME delivering precision medicine to OC patients.Entities:
Mesh：
Year: 2021 PMID： 33903730 PMCID： PMC8368180 DOI： 10.1038/s41416-021-01331-y
Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640